Children and adolescents with sickle cell anemia who received the adenosine diphosphate–directed antiplatelet agent prasugrel had no significant reduction in painful vasoocclusive crises compared with those who received placebo, found a trial conducted in 13 countries (Heeney MM et al. N Engl J Med. doi:10.1056/NEJMoa1512021 [published online December 8, 2015]). Previous studies had suggested that prasugrel reduced markers of platelet activation and, consequently, the rate and intensity of vasoocclusive pain in sickle cell anemia.
from JAMA Current Issue http://ift.tt/1mTvAi9
via IFTTT
No comments:
Post a Comment